Total Payments
$6,543
2022 Payments
$277.70
Companies
8
Transactions
25
Medicare Patients
1,063
Medicare Billing
$147,826
Payment Breakdown by Category
Consulting$3,750 (57.3%)
Travel$1,587 (24.2%)
Food & Beverage$1,169 (17.9%)
Education$37.52 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $3,750 | 1 | 57.3% |
| Travel and Lodging | $1,587 | 7 | 24.2% |
| Food and Beverage | $1,169 | 14 | 17.9% |
| Education | $37.52 | 3 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,441 | 7 | $0 (2019) |
| Radius Health, Inc. | $1,391 | 8 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $264.90 | 2 | $0 (2022) |
| Exelixis Inc. | $225.00 | 3 | $0 (2018) |
| Relypsa, Inc. | $123.59 | 1 | $0 (2018) |
| Clovis Oncology, Inc. | $60.00 | 1 | $0 (2017) |
| PFIZER INC. | $25.60 | 2 | $0 (2022) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $277.70 | 3 | AstraZeneca Pharmaceuticals LP ($264.90) |
| 2021 | $24.72 | 2 | PFIZER INC. ($12.80) |
| 2019 | $5,206 | 10 | Novartis Pharmaceuticals Corporation ($3,816) |
| 2018 | $198.59 | 2 | Relypsa, Inc. ($123.59) |
| 2017 | $835.62 | 8 | Novartis Pharmaceuticals Corporation ($625.62) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/20/2022 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $132.45 | General |
| Category: Oncology | ||||||
| 04/20/2022 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $132.45 | General |
| Category: Oncology | ||||||
| 01/12/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2021 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 10/24/2019 | Radius Health, Inc. | — | Travel and Lodging | Cash or cash equivalent | $55.72 | General |
| 10/05/2019 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: ONCOLOGY | ||||||
| 10/05/2019 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $65.63 | General |
| Category: ONCOLOGY | ||||||
| 09/14/2019 | Radius Health, Inc. | — | Travel and Lodging | In-kind items and services | $304.07 | General |
| 09/14/2019 | Radius Health, Inc. | — | Food and Beverage | In-kind items and services | $107.29 | General |
| 09/14/2019 | Radius Health, Inc. | — | Food and Beverage | In-kind items and services | $90.78 | General |
| 09/14/2019 | Radius Health, Inc. | — | Food and Beverage | In-kind items and services | $50.37 | General |
| 09/14/2019 | Radius Health, Inc. | — | Food and Beverage | In-kind items and services | $46.99 | General |
| 09/13/2019 | Radius Health, Inc. | — | Travel and Lodging | In-kind items and services | $455.60 | General |
| 09/13/2019 | Radius Health, Inc. | — | Travel and Lodging | In-kind items and services | $280.00 | General |
| 09/29/2018 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Oncology | ||||||
| 05/16/2018 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $123.59 | General |
| Category: Hyperkalemia | ||||||
| 09/23/2017 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Oncology | ||||||
| 09/23/2017 | Clovis Oncology, Inc. | Rubraca (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: Oncology | ||||||
| 08/19/2017 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Oncology | ||||||
| 03/10/2017 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Travel and Lodging | In-kind items and services | $281.37 | General |
| Category: ONCOLOGY | ||||||
| 03/10/2017 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Travel and Lodging | Cash or cash equivalent | $175.83 | General |
| Category: ONCOLOGY | ||||||
| 03/10/2017 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $125.73 | General |
| Category: ONCOLOGY | ||||||
| 03/10/2017 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Travel and Lodging | In-kind items and services | $34.00 | General |
| Category: ONCOLOGY | ||||||
| 03/10/2017 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | Cash or cash equivalent | $8.69 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 260 | 449 | $216,904 | $34,363 |
| 2022 | 5 | 235 | 371 | $182,286 | $28,050 |
| 2021 | 6 | 300 | 618 | $259,554 | $52,101 |
| 2020 | 5 | 268 | 458 | $176,139 | $33,312 |
Total Patients
1,063
Total Services
1,896
Medicare Billing
$147,826
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 137 | 242 | $121,484 | $17,276 | 14.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 27 | 49 | $34,251 | $5,853 | 17.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 21 | 73 | $18,131 | $4,807 | 26.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 26 | 26 | $22,152 | $3,735 | 16.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 49 | 59 | $20,886 | $2,692 | 12.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 119 | 201 | $97,998 | $14,084 | 14.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 33 | 43 | $29,173 | $4,745 | 16.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 12 | 44 | $17,071 | $3,668 | 21.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 20 | 20 | $16,507 | $2,854 | 17.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 51 | 63 | $21,537 | $2,698 | 12.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 32 | 180 | $62,460 | $15,489 | 24.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 53 | 128 | $72,370 | $14,901 | 20.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 116 | 167 | $72,176 | $11,605 | 16.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 28 | 28 | $21,940 | $4,154 | 18.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 15 | 51 | $11,577 | $3,048 | 26.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 56 | 64 | $19,031 | $2,904 | 15.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 132 | 194 | $69,030 | $10,472 | 15.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 59 | 106 | $50,270 | $9,301 | 18.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 22 | 101 | $32,724 | $8,959 | 27.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 24 | 24 | $15,834 | $3,267 | 20.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 31 | 33 | $8,281 | $1,313 | 15.9% |
About Dr. Helen Chew, M.D
Dr. Helen Chew, M.D is a Hematology & Oncology healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1801870142.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Helen Chew, M.D has received a total of $6,543 in payments from pharmaceutical and medical device companies, with $277.70 received in 2022. These payments were reported across 25 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($3,750).
As a Medicare-enrolled provider, Chew has provided services to 1,063 Medicare beneficiaries, totaling 1,896 services with total Medicare billing of $147,826. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Sacramento, CA
- Active Since 11/30/2005
- Last Updated 08/22/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1801870142
Products in Payments
- KISQALI (Drug) $4,441
- ENHERTU (Biological) $264.90
- Cabometyx (Drug) $225.00
- Veltassa (Drug) $123.59
- Rubraca (Drug) $60.00
- IBRANCE (Drug) $25.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Sacramento
Dr. Joseph Tuscano, M.d, M.D
Hematology & Oncology — Payments: $633,262
Hematology & Oncology $633,262
Adam Giermasz, M.d., Phd, M.D., PHD
Hematology & Oncology — Payments: $518,605
Hematology & Oncology $518,605
Dr. David Gandara, M.d, M.D
Hematology & Oncology — Payments: $462,968
Hematology & Oncology $462,968
Dr. Scott Christensen, M.d, M.D
Hematology & Oncology — Payments: $391,606
Hematology & Oncology $391,606
Karen Kelly, M.d, M.D
Hematology & Oncology — Payments: $306,992
Hematology & Oncology $306,992
Paul Kaesberg, M.d, M.D
Hematology & Oncology — Payments: $221,939
Hematology & Oncology $221,939